Each episode of the Physiological Reviews podcast features commentary and discussion of newly published articles in the journal, which provides state-of-the-art, comprehensive, and high-impact coverage of timely issues in the physiological and biomedical sciences. Physiological Reviews articles appeal to physiologists, neuroscientists, cell biologists, biophysicists, and clinicians with special interest in pathophysiology. The journal is very useful in teaching and research because it provides non-biased and clearly written updates on important developments.
All content for Physiological Reviews Podcast is the property of American Physiological Society and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Each episode of the Physiological Reviews podcast features commentary and discussion of newly published articles in the journal, which provides state-of-the-art, comprehensive, and high-impact coverage of timely issues in the physiological and biomedical sciences. Physiological Reviews articles appeal to physiologists, neuroscientists, cell biologists, biophysicists, and clinicians with special interest in pathophysiology. The journal is very useful in teaching and research because it provides non-biased and clearly written updates on important developments.
What is the difference between forward and reverse cardio-oncology? In our latest episode, Deputy Editor Dr. Carol Ann Remme (University of Amsterdam) interviews Dr. Rudolf de Boer (Erasmus Medical Center) about the new Review article by Meijers et al. Forward cardio-oncology focuses on cardiotoxicity and cardiac damage due to anti-cancer therapies in patients with prevalent cancer. In contrast, reverse cardio-oncology describes the phenomenon that cancer is more often discovered in patients with prevalent cardiovascular disease. In the more established field of forward cardio-oncology, the focus has been on the diverse array of anti-cancer drugs used to treat different types of cancer that are associated with wide-ranging cardiotoxic effects, such as atrial fibrillation and venous embolism. The developing field of reverse cardio-oncology was launched by initial observations made in clinical registries where the incidence of cancer was common among patients with heart failure. Clinical observations led to the development of murine models of cancer which found the presence of heart failure accelerated tumor growth and considered possible pro-oncogenic factors such as cytokines and extracellular vesicles, along with the microbiome and the immune system. One multifactorial disease is often clinically associated with another multifactorial disease, and underlying physiological mechanisms are complex and multifactorial as well. To learn more, listen now.
Wouter C. Meijers, Joseph Pierre Aboumsallem, Alexander R. Lyon, Javid Moslehi, and Rudolf A. de Boer Forward and reverse cardio-oncology Physiological Reviews, published September 22, 2025. DOI: 10.1152/physrev.00041.2024
Physiological Reviews Podcast
Each episode of the Physiological Reviews podcast features commentary and discussion of newly published articles in the journal, which provides state-of-the-art, comprehensive, and high-impact coverage of timely issues in the physiological and biomedical sciences. Physiological Reviews articles appeal to physiologists, neuroscientists, cell biologists, biophysicists, and clinicians with special interest in pathophysiology. The journal is very useful in teaching and research because it provides non-biased and clearly written updates on important developments.
